Recent Corporate Events:
August 2008: The Company announced that the FDA granted orphan drug designation for our lead drug candidate, MP-470, for the treatment of glioblastoma multiforme (GBM), an often fatal form of brain cancer. The FDA accepted the Company's application upon review of data from in vitro studies in glioblastoma cell lines that demonstrated that either MP-470 or ionizing radiation (IR) alone induce cell death, but when used in combination they synergistically increase cell death by more than two-fold over either agent alone. MP-470 is currently being evaluated in Phase 1 trials as a single agent and in combination with chemotherapy in patients with solid tumors. A Phase 1b study in patients with GBM is planned.
October 2008: The Company presented five posters at the 20th
EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" on
October 23 and 24, 2008. The poster presentations reviewed clinical and
non-clinical advances in MP-470, SGI-1252 and SGI-1776. Poster
presentations included the following abstracts:
-- Abstract 403: Clinical responses in highly refractory solid tumor
patients with oral MP-470, a multi-targeted tyrosine kinase inhibitor,
in combination with standard of care chemotherapy regimens: preliminary
report from a multi-institutional Phase-1b clinical trial.
-- Abstract 332: In vivo activity of SGI-1776, an orally active PIM
-- Abstract 426: Effects of food on the single-dose pharmacokinetics of
oral MP-470 capsules.
-- Abstract 480: MP-470, a novel multi-targeted tyrosine kinase inhibitor
targeting Rad51 is not toxic to human primary ma
|SOURCE SuperGen, Inc.|
Copyright©2008 PR Newswire.
All rights reserved